Proteus Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Proteus syndrome (PS) is an exceptionally rare and intricate disorder characterized by excessive growth in the skeletal, skin, adipose tissue, and central nervous system. Causal mutations for PS have been identified in two components of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway: PTEN, linking PS to the PTEN Hamartoma Tumor Syndrome (PTHS), and AKT1. The AKT1 mutation is typically a somatic mosaic mutation, found in 1-47% of cases. Newborns with PS usually appear normal at birth. Symptoms typically manifest between 6 and 18 months of age and often involve asymmetric overgrowth, primarily in the hands or feet. Macrodactyly, characterized by abnormally large digits, is the most common initial symptom, often accompanied by hemihypertrophy. Skeletal overgrowth can progress rapidly, resulting in irregular, distorted, and calcified growth in the tubular bones of the limbs, skull, and vertebral bodies. Diagnosing PS relies on specific clinical criteria. To establish a diagnosis, patients must meet the general criteria, which include the mosaic distribution of lesions, sporadic occurrence, and a progressive course. Additionally, patients must meet either one of the specific category A criteria (CCTN), two category B criteria (asymmetric disproportionate overgrowth, linear epidermal nevus, specific tumors before the 2nd decade), or three category C criteria (vascular malformations, dysregulated adipose tissue, distinct facial phenotype). Failure to meet these criteria may result in a diagnosis of Proteus-like syndrome. Molecular genetic testing can confirm the diagnosis. Differential diagnoses for PS encompass Klippel-Trenaunay-Weber syndrome, hemihypertrophy, Ollier disease, macrodactyly, Maffucci syndrome, CLOVE syndrome, neurofibromatosis type 1, and other PTEN Hamartoma Tumor Syndrome disorders. Managing PS requires a multidisciplinary approach. Interventions to control the excessive growth of tubular bones may include epiphysiostasis, epiphysiodesis, and, in severe cases, amputation.

·       Proteus syndrome is a rare condition with an incidence of less than 1 in a million people worldwide.

 

Thelansis’s “Proteus Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Proteus Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Proteus Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Proteus Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Proteus Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Proteus Syndrome, Proteus Syndrome market outlook, Proteus Syndrome competitive landscape, Proteus Syndrome market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)